Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Babajide, Keshinro"'
Autor:
Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThis phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consec
Externí odkaz:
https://doaj.org/article/65e3268d9a954502879e597a8bb39643
Autor:
Hugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, Tansy Edwards, Anton Camacho, Grace Mambula, Darius Tetsa-Tata, Edward Man-Lik Choi, Soumah Aboubacar, Hannah Brindle, Chrissy Roberts, Daniela Manno, Benjamin Faguer, Zephyrin Mossoko, Pierre Mukadi, Michel Kakule, Benith Balingene, Esther Kaningu Mapendo, Rockyath Makarimi, Oumar Toure, Paul Campbell, Mathilde Mousset, Robert Nsaibirni, Ibrahim Seyni Ama, Kikongo Kambale Janvier, Babajide Keshinro, Badara Cissé, Mateus Kambale Sahani, John Johnson, Nicholas Connor, Shelley Lees, Nathalie Imbault, Cynthia Robinson, Rebecca F. Grais, Daniel G. Bausch, Jean Jacques Muyembe-Tamfum
Publikováno v:
Vaccines, Vol 12, Iss 8, p 825 (2024)
During the 2018–2020 Ebola virus disease (EVD) outbreak, residents in Goma, Democratic Republic of the Congo, were offered a two-dose prophylactic EVD vaccine. This was the first study to evaluate the safety of this vaccine in pregnant women. Adult
Externí odkaz:
https://doaj.org/article/446d4c0a94ee4c948ee38451ecc7be8c
Autor:
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, Daniel Mukadi-Bamuleka, Aboubacar Soumah, Zephyrin Mossoko, Tansy Edwards, Darius Tetsa-Tata, Rockyath Makarimi, Oumar Toure, Grace Mambula, Hannah Brindle, Anton Camacho, Nicholas E. Connor, Pierre Mukadi, Chelsea McLean, Babajide Keshinro, Auguste Gaddah, Cynthia Robinson, Kerstin Luhn, Julie Foster, Chrissy h. Roberts, John Emery Johnson, Nathalie Imbault, Daniel G. Bausch, Rebecca F. Grais, Deborah Watson-Jones, Jean Jacques Muyembe-Tamfum
Publikováno v:
Vaccines, Vol 12, Iss 8, p 828 (2024)
During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days a
Externí odkaz:
https://doaj.org/article/c5cdadfc1fe648658c2282bb5c3399df
Autor:
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Macaya Douoguih, Cynthia Robinson, Laura Solforosi, Dominika Czapska-Casey, Liesbeth Dekking, Yvonne Wollmann, Ariane Volkmann, Maria Grazia Pau, Benoit Callendret, Jerry Sadoff, Hanneke Schuitemaker, Roland Zahn, Kerstin Luhn, Jenny Hendriks, Ramon Roozendaal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionIn the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals, in a statistical approach called immuno
Externí odkaz:
https://doaj.org/article/aad84e5ba566494dbfbc8dd3349ac928
Autor:
Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, Beatrice Kamala, Daniela Manno, Deborah Watson-Jones, Auguste Gaddah, Babajide Keshinro, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Vaccines, Vol 12, Iss 2, p 210 (2024)
In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, o
Externí odkaz:
https://doaj.org/article/be0eda68b7b14bcebefc7094a6d47a12
Autor:
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Seydou Doumbia, Sodiomon B. Sirima, Alimamy Serry-Bangura, Abdoul Habib Beavogui, Auguste Gaddah, Michael Katwere, Jenny Hendriks, Babajide Keshinro, Serge Eholie, Hannah Kibuuka, Stephen B. Kennedy, Omu Anzala, Mohamed Samai, Eric D'Ortenzio, Bailah Leigh, Samba Sow, Rodolphe Thiébaut, Brian Greenwood, Deborah Watson-Jones, Macaya Douoguih, Kerstin Luhn, Cynthia Robinson
Publikováno v:
EBioMedicine, Vol 91, Iss , Pp 104562- (2023)
Summary: Background: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory.
Externí odkaz:
https://doaj.org/article/98953bd35c35430fa334e7636ba9a326
Autor:
Daniela Manno, Philip Ayieko, David Ishola, Muhammed O. Afolabi, Baimba Rogers, Frank Baiden, Alimamy Serry-Bangura, Osman M. Bah, Brian Köhn, Ibrahim Swaray, Kwabena Owusu-Kyei, Godfrey T. Otieno, Dickens Kowuor, Daniel Tindanbil, Elizabeth Smout, Cynthia Robinson, Babajide Keshinro, Julie Foster, Katherine Gallagher, Brett Lowe, Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 3, Pp 734-738 (2022)
We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014–2016 Ebola outbreak in Sierra Leone, 8% were serop
Externí odkaz:
https://doaj.org/article/2254071766d6435e89e08cf0d179f013
Autor:
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, Kevin Tetteh, Mattu Tehtor Kroma, Godfrey Tuda Otieno, Bolarinde Joseph Lawal, Seyi Soremekun, Philip Ayieko, Auguste Gaddah, Abu Bakarr Kamara, Frank Baiden, Muhammed Olanrewaju Afolabi, Daniel Tindanbil, Kwabena Owusu-Kyei, David Ishola, Gibrilla Fadlu Deen, Babajide Keshinro, Yusupha Njie, Mohamed Samai, Brett Lowe, Cynthia Robinson, Bailah Leigh, Chris Drakeley, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
Vaccines, Vol 11, Iss 8, p 1317 (2023)
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period
Externí odkaz:
https://doaj.org/article/27218876fad04c66bd36a1e1ca9e5ba6
Autor:
Daniela Manno, Agnes Bangura, Frank Baiden, Abu Bakarr Kamara, Philip Ayieko, Joseph Kallon, Julie Foster, Musa Conteh, Nicholas Edward Connor, Bockarie Koroma, Yusupha Njie, Paul Borboh, Babajide Keshinro, Bolarinde Joseph Lawal, Mattu Tehtor Kroma, Godfrey Tuda Otieno, Abdul Tejan Deen, Edward Man-Lik Choi, Ahmed Dahiru Balami, Auguste Gaddah, Chelsea McLean, Kerstin Luhn, Hammed Hassan Adetola, Gibrilla Fadlu Deen, Mohamed Samai, Brett Lowe, Cynthia Robinson, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
The Lancet Infectious Diseases. 23:352-360
Children account for a substantial proportion of cases and deaths during Ebola virus disease outbreaks. We aimed to evaluate the safety and immunogenicity of a booster dose of the Ad26.ZEBOV vaccine in children who had been vaccinated with a two-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a42bac661c5a996dff2ae510780a2a
https://doi.org/10.1016/s1473-3099(22)00594-1
https://doi.org/10.1016/s1473-3099(22)00594-1
Autor:
Francis Kiweewa, Allahna Esber, Ezra Musingye, Domonique Reed, Trevor A Crowell, Fatim Cham, Michael Semwogerere, Rosemary Namagembe, Alice Nambuya, Cate Kafeero, Allan Tindikahwa, Leigh Anne Eller, Monica Millard, Huub C Gelderblom, Babajide Keshinro, Yakubu Adamu, Jonah Maswai, John Owuoth, Valentine Chepkorir Sing'oei, Lucas Maganga, Emmanuel Bahemana, Samoel Khamadi, Merlin L Robb, Julie A Ake, Christina S Polyak, Hannah Kibuuka
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0211344 (2019)
IntroductionThe 2016 WHO consolidated guidelines on the use of antiretroviral drugs defines HIV virologic failure for low and middle income countries (LMIC) as plasma HIV-RNA ≥ 1000 copies/mL. We evaluated virologic failure and predictors in four A
Externí odkaz:
https://doaj.org/article/78215d7ef2cb49d8981af966cb40d96c